Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for..